Janssen (JNJ) Submits Supplemental Biologics License Application to FDA to Expand Indication for DARZALEX (daratumumab)
Tweet Send to a Friend
Janssen Biotech, Inc. (NYSE: JNJ) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
